Sab Biotherapeutics Inc. is a biotechnology company dedicated to developing advanced immunotherapies through its innovative platform for producing polyclonal antibodies. The primary purpose of the company is to harness the power of the human immune system to treat and prevent a wide range of infectious diseases and immune system disorders. Sab Biotherapeutics has developed a proprietary technology that uses transgenic cattle to produce fully human antibodies, offering a scalable and efficient process to meet the demand for antibody therapies. Notably, the company's approach enables rapid response to emerging pathogens, making it a key player in the global health sector where infectious disease outbreaks pose significant challenges. Its technology holds promise across various therapeutic areas, from combating infectious diseases to addressing autoimmune conditions and even offering solutions in oncology. In the financial markets, Sab Biotherapeutics represents a growing segment of biotech firms dedicated to biopharmaceutical innovations. The company’s advancements contribute to the evolving landscape of therapeutic solutions, highlighting the potential for biotechnology to revolutionize treatment paradigms and enhance public health resilience.